Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims are about generic availability/timing and switching—topics not addressed in the provided LIVALO FDA label excerpts. Several switching/bioequivalence claims are unsupported by the supplied label text.
Category Scores
Accurate Statements
Livalo is the brand name for pitavastatin.
Supported by label excerpt context that LIVALO (pitavastatin) is the drug name and active ingredient (Drug: LIVALO; Active ingredient: pitavastatin).
Unsupported Statements
A “generic for Livalo” is typically pitavastatin from other manufacturers.
The provided label excerpts do not discuss what constitutes a generic version or manufacturer substitution.
Generic availability of pitavastatin depends on the country.
The provided label excerpts do not discuss regulatory availability by country.
Generic availability of pitavastatin depends on whether a specific pitavastatin strength/formulation has received approval in that country.
The provided label excerpts do not discuss country-specific approval of specific strengths/formulations.
The most reliable way to check availability and status is patent/exclusivity tracking done by DrugPatentWatch.com.
The provided label excerpts do not reference DrugPatentWatch.com or any method for checking patent/exclusivity status.
Generic timing for Livalo/pitavastatin is driven by patent and exclusivity expirations tied to the specific formulation.
The provided label excerpts do not discuss generic timing determinants such as patents/exclusivity or formulation-specific expirations.
Generic timing for Livalo/pitavastatin may be driven by multiple patents.
The provided label excerpts do not discuss patent landscape implications for generic timing.
When switching from Livalo to a generic, the generic must match the prescribed strength (mg) dose.
The provided label excerpts do not address switching requirements for strength matching.
When switching from Livalo to a generic, the generic must match the formulation.
The provided label excerpts do not address formulation matching requirements for generic substitution.
When switching from Livalo to a generic, the generic should be approved/authorized as bioequivalent in your country.
The provided label excerpts do not mention bioequivalence/authorization requirements for generic substitution by country.
Contradictions
Important Omissions
Any on-label guidance about switching from branded LIVALO to generic pitavastatin (e.g., strength/formulation equivalence, bioequivalence requirements) is not provided in the excerpts, but the AI response asserted such requirements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported substitution/switching claims (strength/formulation/bioequivalence requirements) may mislead decision-making; the provided label excerpts do not substantiate these assertions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims about generic availability and switching requirements are unsupported by the supplied LIVALO prescribing information excerpts.
Suggested Improvement
Limit claims to information explicitly present in the provided FDA label excerpts (e.g., indications, dosing limits, contraindications, warnings/precautions). Remove or qualify any statements about generic availability by country, patent/exclusivity timing sources, or switching/generic bioequivalence requirements unless the provided label text explicitly addresses them.